Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment

NCT04454476 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT04454476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04454476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1
Overall status
Unknown status
Start date
November 9, 2022
Completion date
December 31, 2025
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, initial-onset gastric cancer, metaplasia, stage i gastric cancer